NEW YORK – Biomarker-driven approaches have transformed the treatment of lung cancer, and advancing knowledge about the genetic underpinnings of the disease has redefined it from a monolithic category to multiple tumor types characterized by the genetic alterations driving them.
Meanwhile, the US Food and Drug Administration has approved a variety of molecularly targeted lung cancer drugs, and treatment guidelines now recommend testing for these biomarkers as part of the standard of care.